论文部分内容阅读
目的探讨慢型克山病(KD)采取美托洛尔和卡托普利治疗对心脏功能的影响。方法选取2011年8月~2015年8月本院接收的120例克山病患者,根据治疗方案的不同分为三组,分别为卡托普利组、美托洛尔组及采用常规治疗的对照组,各40。观察三组临床疗效。结果三组死亡率比较差异无统计学意义(P>0.05),但在数值上,两个实验组死亡率较对照组稍高;同时在心胸比缩小率均显著高于对照组(P<0.05);卡托普利组与美托洛尔组在年住院次数、年住院天数上均显著低于对照组(P<0.05),而前两组组间比较差异均无统计学意义(P>0.05);美托洛尔组较对照组、卡托普利组异位心律消失率均显著高(P<0.05),在ST-T改变消失率上,美托洛尔组显著高于对照组(P<0.05);三组在心功能疗效上比较差异无统计学意义(P>0.05);治疗后,三组血压均显著下降,且卡托普利组显著低于对照组(P<0.05),美托洛尔组疗后心率显著下降,且低于对照组及卡托普利组(P<0.05)。结论慢型克山病采用卡托普利和美托洛尔治疗,可逆转或延缓心肌重构,有降低心脏原因死亡的趋势,减少住院率,且安全可靠,具有推广价值。
Objective To investigate the effect of metoprolol and captopril on cardiac function in chronic Keshan disease (KD). Methods A total of 120 patients with Keshan disease admitted from August 2011 to August 2015 in our hospital were divided into three groups according to the different treatment regimens: captopril group, metoprolol group and conventional treatment Control group, each 40. The clinical efficacy of the three groups was observed. Results There was no significant difference in mortality among the three groups (P> 0.05). However, the mortality rate of the two experimental groups was slightly higher than that of the control group, while the rate of reduction of cardiothoracic ratio was significantly higher than that of the control group (P <0.05) (P <0.05), while there was no significant difference between the two groups (P> 0.05). In the metoprolol group, the rate of ectopic heart rate disappearance was significantly higher than that of the control group and captopril group (P <0.05), and the rate of disappearance of ST-T was significantly higher in the metoprolol group than in the control group (P <0.05). There was no significant difference between the three groups in the curative effect of cardiac function (P> 0.05). After treatment, the blood pressure of the three groups decreased significantly, and the captopril group was significantly lower than the control group (P <0.05) , Metoprolol group heart rate decreased significantly after treatment, and lower than the control group and captopril group (P <0.05). Conclusion The treatment of chronic Keshan disease with captopril and metoprolol can reverse or delay myocardial remodeling, reduce the risk of cardiac death, reduce the hospitalization rate, and is safe and reliable, which has the promotion value.